Table 1.

Expression of GATA3 in 2040 epithelial neoplasms.

Tumor type	Positive/total	% positive
Adrenocortical carcinoma	3/27	(11)
Basal cell carcinoma, skin	61/62	(98)
Benign skin adnexal tumors (see text)	24/24	(100)
Breast, ductal carcinoma, primary	164/179	(92)
Breast, ductal carcinoma, metastatic	49/51	(96)
Breast, lobular carcinoma	38/38	(100)
Colon, adenocarcinoma	2/142	(1)
Endometrium, adenocarcinoma	6/89	(7)
Germ cell tumor, seminoma	0/76
Germ cell tumor, choriocarcinoma	11/11	(100)
Germ cell tumor, endodermal sinus tumor	6/6	(100)
Germ cell tumor, pure embryonal carcinoma	0/5*	(40)
Liver, hepatocellular carcinoma	1/47	(2)
Liver, Cholangiocarcinoma	5/57	(9)
Lung, adenocarcinoma	6/71	(8)
Lung, small cell carcinoma	0/30
Lung, carcinoid	0/11
Small, intestine, carcinoid	0/18
Malignant mesothelioma	37/64	(58)
Merkel cell carcinoma	0/4
Ovary, serous carcinoma	4/73	(6)
Ovary, other carcinomas	0/25
Pancreas, adenocarcinoma	23/62	(37)
Pancreas, neuroendocrine tumor	0/15
Prostate, adenocarcinoma	2/95	(2)
Rectum, adenocarcinoma	0/27
Renal cell carcinoma, chromophobe	18/35	(51)
Renal oncocytoma	6/35	(17)
Renal cell carcinoma, other than chromophobe	3/154	(2)
Salivary gland, adenoid cystic carcinoma	5/17	(29)
Salivary gland, ductal carcinoma	6/14	(43)
Squamous cell carcinoma, skin	25/31	(81)
Squamous cell carcinoma, cervix	7/21	(33)
Squamous cell carcinoma, larynx	8/36	(16)
Squamous cell carcinoma, lung	9/74	(12)
Stomach, adenocarcinoma	6/133	(5)
Thymoma	0/41
Thyroid, papillary carcinoma	3/55	(5)
Thyroid, follicular carcinoma	1/20	(5)
Thyroid, anaplastic carcinoma	1/11	(9)
Urothelial carcinoma, low-grade	22/22	(100)
Urothelial carcinoma, high-grade	27/32	(84)

^*Majority of tumor cells negative, small positive subpopulations of uncertain nature detected in some cases.